Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 67

Results For "24"

2055 News Found

Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP
Drug Approval | May 24, 2025

Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP

Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin


Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025
News | May 23, 2025

Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025


Cupid posts Q4 FY25 consolidated PAT at Rs. 11.51 Cr
News | May 22, 2025

Cupid posts Q4 FY25 consolidated PAT at Rs. 11.51 Cr

The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025


Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr
News | May 22, 2025

Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr

The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025


Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash
Clinical Trials | May 22, 2025

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8


Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr
News | May 21, 2025

Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr

Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24


Global Health posts Q4 FY25 consolidated PAT at Rs. 101.4 Cr
News | May 20, 2025

Global Health posts Q4 FY25 consolidated PAT at Rs. 101.4 Cr

Global Health has posted net profit of Rs. 481.43 crores for the Financial Year ended March 31, 2025


Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr
News | May 18, 2025

Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr

Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025


Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr
News | May 18, 2025

Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr

The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025